Bias in reporting of end points of efficacy and toxicity

“Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer.” By F.E. Vera-Badillo, R. Shapiro, A. Ocana, E. Amir and I.F. Tannock, Annals of oncology (PDF)

Of the 164 studies included in a literature review of Phase III randomized, clinical trials (RCTs) from 1995 to 2011, 32.9 percent had positive results that were not based on the primary endpoint and the authors used spin in an attempt to conceal that bias. In addition, 67 percent of the studies were biased in reporting toxicity. The authors concluded that bias in reporting of outcomes is common for studies with negative primary endpoints, and reporting of toxicity is poor, especially for studies with positive primary endpoints.

Read a synopsis from MedPage Today »

Read the paper » (PDF)

Be Sociable, Share!

Articles & Posts